Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05271292 · ClinicalTrials.gov registry record · Phase 1
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
A Phase 1 study of Small-cell Lung Cancer and Advanced Solid Malignant Tumor, sponsored by Chipscreen Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 11
- Study locations
NCT05271292: Recruiting Phase 1 study of Small-cell Lung Cancer and Advanced Solid Malignant Tumor, sponsored by Chipscreen Biosciences.
NCT05271292 is a Phase 1 study of Small-cell Lung Cancer and Advanced Solid Malignant Tumor that is actively recruiting participants, run by Chipscreen Biosciences. The registered enrollment target is 36 participants, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (84% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05271292, a Phase 1 study of Small-cell Lung Cancer and Advanced Solid Malignant Tumor, is actively recruiting participants, sponsored by Chipscreen Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.
Conditions Studied
Interventions
- DRUG Chiauranib
Study Locations (11)
California
- California Cancer Associates-Encintas - Encinitas
- Providence/St. Joe Cancer Institute/Crosson Cancer Institute - Fullerton
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Massachusetts
- Dana Farber Cancer Institue - Boston
Michigan
- Karmanos Cancer Institute - Detroit
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
Ohio
- Gabrail Cancer Center Research - Canton
Oklahoma
- OU Health - Oklahoma City
Tennessee
- Sarah Cannon Research Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-08-26 |
| Est. Completion | 2025-05 |
| Phase | Phase 1 |
What NCT05271292 shows while recruiting
NCT05271292 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Chiauranib is the first listed.
NCT05271292 lists 11 locations in 10 states (California, Georgia, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05271292 about?
NCT05271292 is a clinical study titled "Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.". This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycle...
What is the current status of trial NCT05271292?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-08-26. Estimated completion is 2025-05.
What conditions does trial NCT05271292 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer, Advanced Solid Malignant Tumor.
What interventions are being tested in trial NCT05271292?
The interventions under investigation include: Chiauranib (DRUG).
Who is sponsoring clinical trial NCT05271292?
This trial is sponsored by Chipscreen Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05271292 being conducted?
This trial has 11 study locations across California, Georgia, Massachusetts, Michigan, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05271292's enrollment target sits among peer trials
36 61st of 79 higher than 18 of 79 other Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI